In the Phase IV design, what aspect relates directly to safety monitoring?

• A. Marketing plan
• B. Methods of monitoring adverse events
• C. Manufacturing controls
• D. Animal studies

Answer: (B)

Phase IV centers on post-marketing safety and real-world use, so the element that ties directly to safety monitoring is how adverse events are tracked and reported. This includes pharmacovigilance activities: collecting adverse event data from diverse sources, assessing severity and potential relationship to the product, and submitting reports to regulators and the sponsor. This ongoing safety surveillance helps detect rare or long-term risks that might not appear in earlier trials and informs risk management decisions.

The other options don’t focus on safety monitoring: a marketing plan guides sales and promotion; manufacturing controls ensure product quality and consistency; animal studies are preclinical and occur before human use.